UPDATED Jan. 5, 2016, with comment from GlySens. Implantable continuous glucose monitor developer GlySens raised $20 million in a Series D round, led by backers from its Series C round and “significant participation from new investors,” the company said today. The San Diego-based company is developing an implantable sensor for monitoring glucose, called the Eclipse, […]
GlySens
Diabetes: FDA OKs extended GlySens trial
GlySens today said the FDA approved the extension of a clinical trial of its implantable continuous glucose monitoring system from 6 months to a year. The GlySens device’s implantable sensor is designed to need calibration no more than twice a month, the San Diego-based company said. “We very much appreciate the timely review and approval by FDA […]